4-<(naphthalen-2-yl)methyl>-3H-1,2,3,5-oxathiadiazole 2-oxide | 127810-37-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4-<(naphthalen-2-yl)methyl>-3H-1,2,3,5-oxathiadiazole 2-oxide
• 英文别名: 4-[(2-naphthalenyl)methyl]-3H-1,2,3,5-oxathiadiazol-2-oxide；4-(2-naphthylmethyl)-1,2,3,5-oxathiadiazole-2-oxide；4-[(2-naphthalenyl)methyl]-3H-1,2,3,5-oxathiadiazole-2-oxide；4-(naphthalen-2-ylmethyl)-5H-1,2,3,5-oxathiadiazole 2-oxide
• CAS: 127810-37-1
• 化学式: C₁₂H₁₀N₂O₂S
• 分子量: 246.29
• InChiKey: JDZJQMZKLLQXMR-UHFFFAOYSA-N

物化性质

• 熔点：
  148-151 °C (decomp)
• 沸点：
  438.8±38.0 °C(Predicted)
• 密度：
  1.48±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  87.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-Hydroxy-2-naphthalen-2-yl-acetamidine 在 吡啶 、 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 0.33h， 生成 4-<(naphthalen-2-yl)methyl>-3H-1,2,3,5-oxathiadiazole 2-oxide
  参考文献：
  名称：

  Antihyperglycemic activity of novel substituted 3H-1,2,3,5-oxathiadiazole 2-oxides

  摘要：

  A series of substituted 3H-1,2,3,5-oxathiadiazole-2-oxides (6) was prepared and tested for antihyperglycemic activity in the db/db mouse, a model for type 2 (non-insulin dependent) diabetes mellitus. The oxathiadiazoles 6 were synthesized by a two-step sequence: treatment of a substituted acetonitrile (4) with hydroxylamine to give the corresponding amidoxime (5) and cyclization with thionyl chloride to yield 6. In terms of potency, the 2-naphthalenylmethyl group (as in compound 3) was found to be the optimal substituent in this series. Compound 3 was approximately 5 times more potent than ciglitazone (1).

  DOI：

  10.1021/jm00085a002

文献信息

• Method of inhibiting angiogenesis
  申请人：Genentech, Inc.

  公开号：US20010036955A1

  公开（公告）日：2001-11-01

  Angiogenesis is inhibited and the growth of tumors is treated by administering an effective amount of a PPAR gamma ligand/agonist, optionally with an RXR receptor ligand.

  血管生成受到抑制，肿瘤生长通过给予有效剂量的PPARγ配体/激动剂进行治疗，可选地与RXR受体配体一起使用。
• Drug comprising combination
  申请人：——

  公开号：US20030060488A1

  公开（公告）日：2003-03-27

  A TNF-&agr; inhibitor comprising an insulin sensitizer in combination with an HMG-CoA reductase inhibitor is useful as an agent for the prophylaxis or treatment of an inflammatory disease and the like.

  一种包含胰岛素增敏剂和HMG-CoA还原酶抑制剂的TNF-α抑制剂，可用作预防或治疗炎症性疾病等的药剂。
• Neovascularization inhibitors
  申请人：——

  公开号：US20030134884A1

  公开（公告）日：2003-07-17

  An angiogenesis inhibitor containing a compound represented by the formula 1 wherein R 4 is an optionally substituted hydrocarbon group and the like; Xa is a bond and the like; k is an integer of 1 to 3; Ya is an oxygen atom and the like; ring Ea is a benzene ring optionally having additional substituent(s); p is an integer of 1 to 8; R 5 is a hydrogen atom and the like; q is an integer of 0 to 6; r is 0 or 1; R 8 is a hydroxy group and the like; and R 6 and R 7 are hydrogen atoms and the like, or a salt thereof is useful as an agent for the prophylaxis or treatment of tumor and the like.

  一种含有由下式表示的化合物的血管生成抑制剂 其中R4是可选择地取代的碳氢基团等；Xa是键等；k是1到3的整数；Ya是氧原子等；环Ea是苯环，可选择地具有额外的取代基；p是1到8的整数；R5是氢原子等；q是0到6的整数；r为0或1；R8是羟基等；R6和R7是氢原子等，或其盐，可用作预防或治疗肿瘤等的药剂。
• Abc expression promoters
  申请人：——

  公开号：US20040077689A1

  公开（公告）日：2004-04-22

  The ABCA1 mRNA expression-promoting agent, LXR&agr; mRNA expression-promoting agent, ABCG1 mRNA expression-promoting agent, cholesterol efflux-promoting agent, cholesteryl ester accumulation-inhibiting agent, ACAT-1 mRNA expression-inhibiting agent and CEH mRNA expression-promoting agent of the present invention are excellent in the ability to control cholesterol distribution in the body and have low toxicity.

  本发明的ABCA1 mRNA表达促进剂、LXRα mRNA表达促进剂、ABCG1 mRNA表达促进剂、胆固醇外流促进剂、胆固醇酯积聚抑制剂、ACAT-1 mRNA表达抑制剂和CEH mRNA表达促进剂在控制体内胆固醇分布方面具有出色的能力和低毒性。
• Pharmaceutical composition for use in tteatment of diabetes
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0749751A2

  公开（公告）日：1996-12-27

  Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

  药物组合物，其中包括一种胰岛素敏感性增强剂与其他抗糖尿病药物的组合，这些药物的作用机理与增强剂不同，对糖尿病高血糖具有强效抑制作用，可用于预防和治疗糖尿病。